Priority setting for orphan drugs: An international comparison

Health Policy

Volumn 100, Issue 1, 2011, Pages 25-34

  Rosenberg Yunger, Zahava R S ^a   Daar, Abdallah S ^b   Thorsteinsdóttir, Halla ^b   Martin, Douglas K ^c  

^a MCMASTER CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Decision making; Orphan drugs; Priority setting

Indexed keywords

AGALSIDASE BETA; IMIGLUCERASE;

ADVISORY COMMITTEE; ARTICLE; AUSTRALIA; CANADA; CASE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; FABRY DISEASE; FUNDING; GAUCHER DISEASE; GEOGRAPHIC DISTRIBUTION; HUMAN; INTERVIEW; ISRAEL; PATIENT; QUALITATIVE RESEARCH; REIMBURSEMENT; RESEARCH PRIORITY;

ADVISORY COMMITTEES; ALPHA-GALACTOSIDASE; AUSTRALIA; CANADA; DECISION MAKING, ORGANIZATIONAL; DRUG COSTS; DRUG INDUSTRY; GLUCOSYLCERAMIDASE; HEALTH POLICY; HEALTH PRIORITIES; HUMANS; INTERVIEWS AS TOPIC; ISOENZYMES; ISRAEL; ORPHAN DRUG PRODUCTION;

EID: 79952606431     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.09.008     Document Type: Article

References (46)

1. The European Union and the FDA working together to create Common Application for Orphan Designation for Medicines [cited 2010 June 28]. Available from: http://www.ema.europa.eu/pdfs/general/direct/pr/55739107en.pdf.
2. Clarke J.T.R. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ 2006, 174(2).
3. Hollis A. Drugs for rare diseases: paying for innovation. Health services restructuring in Canada: new evidence and new directions 2006, 155-178. McGill-Queen's University Press, Montreal. C.M. Beach (Ed.).
4. CORD. Towards a Canadian Orphan Drug Policy; 2005 [cited 2008 April 7]. Available from: http://www.fragile-x.ca/advocacy%2520files/Canada's%2520Orphan%2520Drug%2520Polic%2520y%25200805.pdf.
5. Ries, Lag, Harkins, D, Krapcho, M, Mariotto, A, Miller, BA, Feuer, EJ, et al. Probability of Breast Cancer in American Women. National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Program has published its SEER Cancer Statistics Review 1975-2003 2006 [cited 2009 December 30]. Available from: http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer.
6. Laino C. Targeted Breast Cancer Drug Shrinks Tumors; 2009 [cited 2009 December 30]. Available from: http://www.medicinenet.com/script/main/art.asp?articlekey=109470.
7. Gallego G., Taylor S.J., Brien J.A. Priority setting for high cost medications (HCMs) in public hospitals in Australia: a case study. Health Policy 2007, 84(1):58-66.
8. Kesselman I., Elstein D., Israeli A., Chertkoff R., Zimran A. National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model. Blood Cells Molecules and Diseases 2006, 37(1):46-49.
9. National Gaucher Foundation of Canada [cited 2010 July 19]. Available from: http://www.gauchercanada.ca/en/gaucher.html.
10. Elstein D., Abrahamov A., Hadas-Halpern I., Meyer A., Zimran A. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. Quarterly Journal of Medicine 1998, 91:483-488.
11. Barton N.W., Brady R.O., Dambrosia J.M. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. New England Journal of Medicine 1991, 324(21):1464-1470.
12. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., McKee M.A., et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Annals of Internal Medicine 1995, 122(1):33-39.
13. Zimran A., Elstein D., Levy-Lahad E., Zevin S., Hadas-Halpern I., Bar-Ziv Y., et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995, 10(345):1479-1480.
14. Lysosomal Disease Program Fabry Disease Description [cited 2010 July 19]. Available from: http://www.mghlysosomal.org/Fabry.html.
15. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., et al. Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. New England Journal of Medicine 2001, 345(1).
16. Banikazemi M., Bultas J., Waldek S., Wilcox W.R., Whitely C.B., McDonald M., et al. Agalsidase-beta therapy for advanced Fabry disease. Annals of Internal Medicine 2007, 146(2).
17. Schiffmann R., Ries M., Timmons M., Flaherty J.T., Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrology Dialysis Transplantation 2006, 21:345-354.
18. Wilcox W.R., Banikazemi M. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. American Journal of Human Genetics 2004, 75:65-74.
19. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285(21):2743-2749.
20. CEDAC [cited 2007 November 17]. Available from: http://www.cadth.ca/index.php/en/cdr/committees/cedac.
21. PBAC [cited 2008 December 31]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/PBAC-Meeting-Agenda-and-Consumer-Comments-lp.
22. Shani S., Siebzhner M.I., Luxenburg O., Shemer J. Setting priorities for the adoption of health technologies on a national level-the Israeli Experience. Health Policy 2000, 54:169-185.
23. Ceredase and cerezyme [cited 2003 June 13]. Available from: http://www.ghimedicare.com/drafts/ceredase.html.
24. Rx-List [cited 2005 February 18]. Available from: http://www.rxlist.com/cgi/generic3/fabrazyme.htm.
25. Maxwell J.A. Qualitative research design: an interactive approach. Applied social research methods series 1996, vol. 41. Sage Publications, London.
26. Strauss A., Corbin J. Basics of qualitative research: techniques and procedures for developing grounded theory 1998, Sage Publications, Thousand Oaks. 2nd ed.
27. The sage handbook of qualitative research 2005, Sage Publications, London. 3rd ed. N.K. Denzin, Y.S. Lincoln (Eds.).
28. Creswell J.W. Qualitative inquiry and research design: choosing among five traditions 1998, Sage Publications, London.
29. Werber Y. Lysosomal storage disease market. Nature Reviews Drug Discovery 2004, 3:9-10.
30. Clarke J.T.R., Amato D., Deber R.B. Managing public payment for high cost, high-benefit therapy for Gaucher's disease in Ontario. CMAJ 2001, 165(5):595.
31. Alternative Arrangements for Medicines: Life Saving Drugs [cited 2008 March 12]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-supply-othersupply.
32. Guidelines for the Treatment of Gaucher Disease [cited 2007 August 14]. Available from: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/71D15BD1EE4A4A8DCA256F85007A7F66/$File/gguidelines.pdf.
33. Gross M. Ethics, policy, and rare genetic disorders: the case of Gaucher disease in Israel. Theoretical Medicine and Bioethics 2002, 23(2):151-170.
34. Hollak C.E., de Fost M., van Dussen L., Vom Dahl S., Aerts J.M. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose-response relationships. Expert Opinion on Pharmacotherapy 2009, 10(16):2641-2652.
35. CEDAC. CDR drug database listing on agalsidase beta; 2005 [cited 2007 November 17]. Available from: http://www.cadth.ca/index.php/en/cdr/search/%3F%26status=all%26keywords=agalsidase%2520beta.
36. Cookson R., McCabe C., Tsuchiya A. Public healthcare resource allocation and the Rule of Rescue. Journal of Medical Ethics 2008, 34:540-544.
37. Dean M. Is your treatment economic, effective efficient?. British Medical Journal 1991, 337:480-481.
38. Coast J. The case against. British Medical Journal 1997, 314(7087):1118.
39. Sabin J. Fairness as a problem of love and the heart: a clinician's perspective on priority setting in health care. British Medical Journal 1998, 317(7164):1000-1007.
40. Klein R. Dimensions of rationing: who should do what?. British Medical Journal 1993, (4):309-311.
41. World Development Report 2004: Making Services Work For Poor People.
42. Loughlin M. Rationing, barbarity and the economist's perspective. Health Care Analysis 1996, 4(2):146-156.
43. Martin D.K., Peter S. Priority setting and health technology assessment: beyond evidence-based medicine and cost-effective analysis. The global challenge of health care rationing 2000, 133-135. Open University Press, Philadelphia. A. Coulter, C. Ham (Eds.).
44. Hughes D.A., Tunnage B., Yeo S.T. Drugs for exceptionally rare diseases: do they deserve special status for funding?. QJM 2005, 98(11):829-836.
45. Martin D.K., Pater J.L., Singer P.A. Priority-setting decisions for new cancer drugs: a qualitative case study. Lancet 2001, 358(9294):1676-1681.
46. Panju A., Bell C. Policy alternatives for treatments for rare diseases. CMAJ 2010.